Abbelight joins The HIVE as the first Central Lab partner, strengthening the life sciences ecosystem at Campus Grand Parc
Villejuif, 10/11/2026 – Kadans Science Partner announces the arrival of Abbelight at The HIVE, located within Campus Grand Parc in Villejuif. Specializing in nanoscopy and quantitative studies to characterize and compare drug candidates under development, Abbelight becomes the first company to join The HIVE’s Central Lab. This milestone marks an important step in the development of the campus life sciences ecosystem by providing resident companies with local access to cutting-edge scientific and technological expertise.
This new location also represents another stage in Abbelight’s journey within the Paris-Saclay Cancer Cluster (PSCC). Supported through the BOOST program and recipient of the BOOST Grant 2026, the company benefits from financial support from the biocluster to advance its oncology project. Its move to The HIVE further strengthens the connections between PSCC-supported companies and the technological expertise available on campus.
Unique expertise supporting the development of biotherapies.
Abbelight supports life sciences organizations in making critical development decisions through its proprietary nanoscopy imaging technologies and advanced quantitative analysis capabilities. The company enables the characterization of therapeutic target organization, the monitoring of internalization and intracellular trafficking of biologic drugs, and the evaluation of emerging therapeutic modalities including monoclonal antibodies, antibody-drug conjugates (ADCs), messenger RNA (mRNA), lipid nanoparticles, and bispecific antibodies. These approaches provide quantitative data that help accelerate candidate selection, improve understanding of mechanisms of action, and support preclinical development.
Through its model combining scientific expertise, proprietary technology platforms, and outsourced research services, Abbelight plays a strategic role within the biopharmaceutical innovation value chain.
A key building block in the Campus Grand Parc ecosystem
As the 15th company to establish operations at The HIVE, Abbelight’s arrival represents a significant milestone in the development of the Campus Grand Parc ecosystem. As the first company to provide dedicated scientific services to resident organizations, it officially launches the Central Lab, an initiative developed by Kadans Science Partner and the PSCC to provide companies with direct on-campus access to the services, technology platforms, and expertise necessary for their growth and development.
With this first installation, The HIVE takes another step toward its ambition of creating an integrated environment where researchers, entrepreneurs, and industry leaders can collaborate more effectively and accelerate the development of their innovations.
“Our place is where tomorrow’s treatments are being invented: on a campus of excellence, close to our partners. Being the first organization to join The HIVE’s Central Lab is a source of great pride for the entire Abbelight team.” says Quentin Lubart, Business Development Director at Abbelight
“Abbelight perfectly illustrates the complementary tools we deploy within the PSCC: project support, BOOST Grant funding, and access to a world-class scientific and clinical ecosystem. We have been delighted to support their development since September 2023. By joining The HIVE’s Central Lab, Abbelight brings expertise in nanoscopy imaging that will benefit other innovators in oncology. This spirit of knowledge sharing is exactly the dynamic we aim to foster across the campus.” declares Benjamin Garel, Chief Executive Officer of the Paris-Saclay Cancer Cluster.
“Abbelight’s arrival is particularly significant for the ecosystem we are building at The HIVE and across Campus Grand Parc. By welcoming a CRO capable of supporting the development of therapeutic innovations, we strengthen the complementarity of expertise available on site and create additional synergies between companies, researchers, and industrial partners.” explain Elise Colla, Head of Business Development France at Kadans Science Partner.
